68 Ga-prostate-specific membrane antigen (PSMA) PET/CT as a clinical decision-making tool in biochemically recurrent prostate cancer.
Amy DaviesMarcus FooChun Loo GanJohn KourambasNicholas RedgraveScott DonnellanSree AppuScott WilliamsAndrew ColemanEva SegelovJason BradleyGeoffrey SooShakher RamdaveEdmond M KwanArun A AzadPublished in: Asia-Pacific journal of clinical oncology (2021)
Management change after 68 Ga-PSMA PET/CT for BCR is common and typically resulted in treatment intensification strategies in those planned for a watchful waiting approach. This study adds to the growing pool of evidence supporting the clinical utility of PSMA PET/CT imaging in the care of patients with BCR after definitive therapy.
Keyphrases
- pet ct
- prostate cancer
- acute lymphoblastic leukemia
- decision making
- tyrosine kinase
- positron emission tomography
- radical prostatectomy
- healthcare
- chronic myeloid leukemia
- high resolution
- palliative care
- quality improvement
- pain management
- stem cells
- squamous cell carcinoma
- locally advanced
- benign prostatic hyperplasia
- fluorescence imaging
- combination therapy
- rectal cancer
- chronic pain
- cell therapy
- affordable care act